Evasion of Adaptive Immunity by HIV Through the Action of Host APOBEC3G/F Enzymes

Overview

Journal AIDS Res Ther

Publisher Biomed Central

Specialty Infectious Diseases

Date 2017 Sep 13

PMID 28893290

Citations 13

Authors

Michael Grant

Mani Larijani

Affiliations

Soon will be listed here.

Abstract

APOBEC3G (A3G) and APOBEC3F (A3F) are DNA-mutating enzymes expressed in T cells, dendritic cells and macrophages. A3G/F have been considered innate immune host factors, based on reports that they lethally mutate the HIV genome in vitro. In vivo, A3G/F effectiveness is limited by viral proteins, entrapment in inactive complexes and filtration of mutations during viral life cycle. We hypothesized that the impact of sub-lethal A3G/F action could extend beyond the realm of innate immunity confined to the cytoplasm of infected cells. We measured recognition of wild type and A3G/F-mutated epitopes by cytotoxic T lymphocytes (CTL) from HIV-infected individuals and found that A3G/F-induced mutations overwhelmingly diminished CTL recognition of HIV peptides, in a human histocompatibility-linked leukocyte antigen (HLA)-dependent manner. Furthermore, we found corresponding enrichment of A3G/F-favored motifs in CTL epitope-encoding sequences within the HIV genome. These findings illustrate that A3G/F-mediated mutations mediate immune evasion by HIV in vivo. Therefore, we suggest that vaccine strategies target T cell or antibody epitopes that are not poised for mutation into escape variants by A3G/F action.

Citing Articles

Leong S, Nasser H, Ikeda T Int J Mol Sci. 2025; 26(4).

PMID: 40004025 PMC: 11855278. DOI: 10.3390/ijms26041561.

Army liposome formulation containing QS-21 render human monocyte-derived macrophages less permissive to HIV-1 infection by upregulating ABOBEC3A.

Jobe O, Kim J, Pinto D, Villar Z, Hewitt T, Duncan E Sci Rep. 2022; 12(1):7570.

PMID: 35534646 PMC: 9082986. DOI: 10.1038/s41598-022-11230-8.

Structure-Based Design of First-Generation Small Molecule Inhibitors Targeting the Catalytic Pockets of AID, APOBEC3A, and APOBEC3B.

King J, Borzooee F, Im J, Asgharpour M, Ghorbani A, Diamond C ACS Pharmacol Transl Sci. 2021; 4(4):1390-1407.

PMID: 34423273 PMC: 8369683. DOI: 10.1021/acsptsci.1c00091.

Human APOBEC3 Variations and Viral Infection.

Sadeghpour S, Khodaee S, Rahnama M, Rahimi H, Ebrahimi D Viruses. 2021; 13(7).

PMID: 34372572 PMC: 8310219. DOI: 10.3390/v13071366.

Potential Utilization of APOBEC3-Mediated Mutagenesis for an HIV-1 Functional Cure.

Ikeda T, Yue Y, Shimizu R, Nasser H Front Microbiol. 2021; 12:686357.

PMID: 34211449 PMC: 8239295. DOI: 10.3389/fmicb.2021.686357.

References

Yu X, Yu Y, Liu B, Luo K, Kong W, Mao P . Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science. 2003; 302(5647):1056-60. DOI: 10.1126/science.1089591. View

Borrow P, Lewicki H, Hahn B, Shaw G, Oldstone M . Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol. 1994; 68(9):6103-10. PMC: 237022. DOI: 10.1128/JVI.68.9.6103-6110.1994. View

Emu B, Sinclair E, Hatano H, Ferre A, Shacklett B, Martin J . HLA class I-restricted T-cell responses may contribute to the control of human immunodeficiency virus infection, but such responses are not always necessary for long-term virus control. J Virol. 2008; 82(11):5398-407. PMC: 2395228. DOI: 10.1128/JVI.02176-07. View

Koning F, Newman E, Kim E, Kunstman K, Wolinsky S, Malim M . Defining APOBEC3 expression patterns in human tissues and hematopoietic cell subsets. J Virol. 2009; 83(18):9474-85. PMC: 2738220. DOI: 10.1128/JVI.01089-09. View

Monajemi M, Woodworth C, Benkaroun J, Grant M, Larijani M . Emerging complexities of APOBEC3G action on immunity and viral fitness during HIV infection and treatment. Retrovirology. 2012; 9:35. PMC: 3416701. DOI: 10.1186/1742-4690-9-35. View

Zhang H, Yang B, Pomerantz R, Zhang C, Arunachalam S, Gao L . The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature. 2003; 424(6944):94-8. PMC: 1350966. DOI: 10.1038/nature01707. View

Altfeld M, Kalife E, Qi Y, Streeck H, Lichterfeld M, Johnston M . HLA Alleles Associated with Delayed Progression to AIDS Contribute Strongly to the Initial CD8(+) T Cell Response against HIV-1. PLoS Med. 2006; 3(10):e403. PMC: 1626551. DOI: 10.1371/journal.pmed.0030403. View

Wood N, Bhattacharya T, Keele B, Giorgi E, Liu M, Gaschen B . HIV evolution in early infection: selection pressures, patterns of insertion and deletion, and the impact of APOBEC. PLoS Pathog. 2009; 5(5):e1000414. PMC: 2671846. DOI: 10.1371/journal.ppat.1000414. View

Belanger K, Savoie M, Gerpe M, Couture J, Langlois M . Binding of RNA by APOBEC3G controls deamination-independent restriction of retroviruses. Nucleic Acids Res. 2013; 41(15):7438-52. PMC: 3753645. DOI: 10.1093/nar/gkt527. View

10.

Yu Q, Konig R, Pillai S, Chiles K, Kearney M, Palmer S . Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome. Nat Struct Mol Biol. 2004; 11(5):435-42. DOI: 10.1038/nsmb758. View

11.

Santa-Marta M, Aires da Silva F, Fonseca A, Goncalves J . HIV-1 Vif can directly inhibit apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3G-mediated cytidine deamination by using a single amino acid interaction and without protein degradation. J Biol Chem. 2004; 280(10):8765-75. DOI: 10.1074/jbc.M409309200. View

12.

Yu Y, Xiao Z, Ehrlich E, Yu X, Yu X . Selective assembly of HIV-1 Vif-Cul5-ElonginB-ElonginC E3 ubiquitin ligase complex through a novel SOCS box and upstream cysteines. Genes Dev. 2004; 18(23):2867-72. PMC: 534647. DOI: 10.1101/gad.1250204. View

13.

Chiu Y . Biochemical fractionation and purification of high-molecular-mass APOBEC3G complexes. Methods Mol Biol. 2011; 718:185-206. DOI: 10.1007/978-1-61779-018-8_12. View

14.

Goncalves J, Santa-Marta M . HIV-1 Vif and APOBEC3G: multiple roads to one goal. Retrovirology. 2004; 1:28. PMC: 521195. DOI: 10.1186/1742-4690-1-28. View

15.

Shankar P, Russo M, Harnisch B, Patterson M, Skolnik P, Lieberman J . Impaired function of circulating HIV-specific CD8(+) T cells in chronic human immunodeficiency virus infection. Blood. 2000; 96(9):3094-101. View

16.

Harris R, Bishop K, Sheehy A, Craig H, Petersen-Mahrt S, Watt I . DNA deamination mediates innate immunity to retroviral infection. Cell. 2003; 113(6):803-9. DOI: 10.1016/s0092-8674(03)00423-9. View

17.

Squires K, Monajemi M, Woodworth C, Grant M, Larijani M . Impact of APOBEC Mutations on CD8+ T Cell Recognition of HIV Epitopes Varies Depending on the Restricting HLA. J Acquir Immune Defic Syndr. 2015; 70(2):172-8. DOI: 10.1097/QAI.0000000000000689. View

18.

Mangeat B, Turelli P, Caron G, Friedli M, Perrin L, Trono D . Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature. 2003; 424(6944):99-103. DOI: 10.1038/nature01709. View

19.

Allen T, Altfeld M, Geer S, Kalife E, Moore C, OSullivan K . Selective escape from CD8+ T-cell responses represents a major driving force of human immunodeficiency virus type 1 (HIV-1) sequence diversity and reveals constraints on HIV-1 evolution. J Virol. 2005; 79(21):13239-49. PMC: 1262562. DOI: 10.1128/JVI.79.21.13239-13249.2005. View

20.

Russell R, Moore M, Hu W, Pathak V . APOBEC3G induces a hypermutation gradient: purifying selection at multiple steps during HIV-1 replication results in levels of G-to-A mutations that are high in DNA, intermediate in cellular viral RNA, and low in virion RNA. Retrovirology. 2009; 6:16. PMC: 2657108. DOI: 10.1186/1742-4690-6-16. View